Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 11, 2021

Rhea-AI Summary

Asensus Surgical, Inc. (NYSE American: ASXC) will release its Q1 2021 financial and operating results after market close on May 11, 2021. A conference call is scheduled for 4:30 p.m. ET, which will also be available via webcast. The company focuses on digitizing the surgeon-patient interface through its Senhance^® Surgical System, aimed at enhancing surgical outcomes with intelligent technology. This includes machine vision and deep learning to address current surgical challenges. The system is currently available for sale in multiple countries including the US, EU, and Japan.

Positive

• Asensus Surgical plans to announce Q1 2021 financial results, indicating ongoing business activities.
• The company is expanding its digital surgical technologies, which could enhance market position.
• Senhance Surgical System is now available in multiple regions, increasing potential revenue streams.

Negative

• None.

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced today that it plans to release 2021 first quarter financial and operating results after the market closes on Tuesday, May 11, 2021. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

To listen to the conference call on your telephone, please dial 1-855-327-6837 for domestic callers and 1-631-891-4304 for international callers, and reference conference ID 10014229 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link https://ir.asensus.com/events-and-presentations. The replay will be available on the Company’s website.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the clinical intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance^® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005152/en/

FAQ

When will Asensus Surgical release its Q1 2021 financial results?

Asensus Surgical will release its Q1 2021 financial results after market close on May 11, 2021.

What is the significance of the Senhance Surgical System?

The Senhance Surgical System aims to improve surgical outcomes by enhancing the surgeon-patient interface with advanced technologies.

How can I access the Asensus Surgical conference call?

You can access the conference call by dialing 1-855-327-6837 for domestic callers or 1-631-891-4304 for international callers, and referencing conference ID 10014229.

Where is the Senhance Surgical System available for sale?

The Senhance Surgical System is available for sale in the US, EU, Japan, Russia, and select other countries.